Kyndryl (NYSE:KD) Q3 2026 Earnings call February 09, 2026 08:30 AM ET Speaker3Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Lori Chaitman, Global Head of Investor Relations. Please go ahead.Speaker7Good morning, everyone, and welcome to Kyndryl's earnings call for the third fiscal quarter ended December 31, 2025. Before we begin, I'd like to remind you that our remarks today include forward-looking statements. These sta ...

Anavex Life Sciences (NasdaqGS:AVXL) Q1 2026 Earnings call February 09, 2026 08:30 AM ET Speaker1Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal 2026 First Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session, and during this session if you would like to ask a question please use the Q&A box or raise your hand. Please note this confere ...

Financial Data and Key Metrics Changes - The company reported an organic net sales decline of 7% year-over-year, driven by lower sales in both North America and international segments [15] - Adjusted gross margin decreased to 19.5%, a drop of approximately 340 basis points year-over-year, primarily due to cost inflation and lower volume mix [15][16] - Adjusted EBITDA was $24 million, down from $38 million a year ago, reflecting lower gross margins [17][18] Business Line Data and Key Metrics Changes - In North America, organic net sales declined 10% year-over-year, primarily due to lower volume in snacks and baby formula, with adjusted gross margin at 20.8%, a decrease of 440 basis points [18][19] - The international segment saw a 3% decline in organic net sales, with adjusted gross margin at 18.1%, a 200 basis point decrease [19][20] - Snacks organic net sales were down 20% year-over-year, while the baby and kids segment saw a 14% decline [20] Market Data and Key Metrics Changes - North American snacks represented 22% of the company's net sales in fiscal 2025 and 38% of the North America segment's net sales, with negligible EBITDA contribution over the last 12 months [8][12] - The core categories in North America, including tea, yogurt, and baby foods, showed stability and growth potential despite challenges in other areas [12][18] Company Strategy and Development Direction - The company is executing a strategic review aimed at simplifying its portfolio, enhancing financial flexibility, and maximizing shareholder value [5][9] - A definitive agreement was reached to sell the North American snacks business for $115 million, with proceeds intended to reduce debt and strengthen the financial position [6][7] - The focus will shift to three flagship categories: tea, yogurt, and baby and kids, while continuing to develop the meal prep platform [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the turnaround strategy, highlighting improvements in operational execution and cash flow [12][14] - The company anticipates stronger top and bottom-line performance in the second half of the year, driven by ongoing initiatives and innovation [27][29] - Management acknowledged near-term pressures but emphasized the importance of strategic actions to drive sustainable growth [12][14] Other Important Information - Free cash flow in the second quarter was $30 million, an increase of 22% compared to the previous year [22] - The company has reduced net debt by $32 million, bringing total net debt to $637 million [23][24] - The strategic review includes plans for further asset sales and operational improvements to enhance financial flexibility [25] Q&A Session Summary Question: Details on the decision to divest the snacks portfolio - Management explained that the decision was part of a strategy to simplify the portfolio and focus on categories where the company has strengths, noting that snacks had become financially challenged [34][35] Question: Reallocation of innovations post-divestiture - Management confirmed plans to mitigate stranded costs of $20 million-$25 million and emphasized that freed resources would support innovation in remaining categories [41][42] Question: Cash generation from the snacks business - Management indicated that the snacks business was not a significant cash generator, and the divestiture would improve overall cash generation capabilities [45] Question: Future growth in the baby and kids business - Management expressed confidence in returning to growth in the baby and kids segment, particularly after cycling past challenges and launching new products [84][85]

Dynatrace (NYSE:DT) Q3 2026 Earnings call February 09, 2026 08:00 AM ET Company ParticipantsAndrew Sherman - Directot and Enterprise SoftwareJim Benson - CFOKoji Ikeda - Director in Enterprise Software Equity ResearchNoelle Faris - VP of Investor RelationsRick McConnell - CEOConference Call ParticipantsBrad Reback - Managing Director and Equity Research AnalystBrent Thill - Tech Sector Leader and Software AnalystDeShaun Fontenot - Software Equity Research AnalystEric Heath - VP and Equity Research AnalystGr ...

Dynatrace (NYSE:DT) Q3 2026 Earnings call February 09, 2026 08:00 AM ET Company ParticipantsAndrew Sherman - Directot and Enterprise SoftwareJim Benson - CFOKoji Ikeda - Director in Enterprise Software Equity ResearchNoelle Faris - VP of Investor RelationsRick McConnell - CEOConference Call ParticipantsBrad Reback - Managing Director and Equity Research AnalystBrent Thill - Tech Sector Leader and Software AnalystEric Heath - VP and Equity Research AnalystGray Powell - Managing Director and Security and Infr ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2026 was $5.3 billion, reflecting a 0.4% increase year-on-year, with New BD growing by 2.5% [5][18] - Adjusted gross margin was 53.4%, down 140 basis points from the prior year, primarily due to tariffs [20] - Adjusted EPS was $2.91, a decrease of 15.2% year-on-year, mainly impacted by tariffs [21] - Free cash flow for the quarter was $548 million, with a conversion rate of 66%, up from 59% in the prior year [22] Business Line Data and Key Metrics Changes - Medical Essentials experienced expected order timing dynamics and volume-based procurement in China, partially offset by share gains in the US [18] - Connected Care delivered mid-single-digit growth, led by high single-digit growth in APM [18] - Biopharma Systems grew low single digits, with double-digit growth in biologics, particularly GLP-1s, offset by lower vaccine demand [19] - Interventional and surgery segments both delivered solid mid-single-digit growth, with strong performance in Advanced Tissue Regeneration [19] Market Data and Key Metrics Changes - The US market showed solid growth in the BD Vacutainer portfolio, while challenges persisted in China due to market dynamics [18] - Alaris performance was slightly ahead of expectations despite a revenue decline due to tough comparisons to the prior year [19] - The Life Sciences segment declined due to US point-of-care headwinds and market dynamics in China [20] Company Strategy and Development Direction - The company is focused on a balanced capital allocation strategy, prioritizing share repurchases and tuck-in M&A in high-growth markets [8][9] - Key trends shaping the future of healthcare include the rise of smart devices, the shift towards lower-cost care settings, and the growth in chronic disease technologies [9][10] - The company aims to enhance its commercial capabilities and operational excellence through its "Excellence Unleashed" strategy, focusing on competing, innovating, and delivering [11][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of the business, with core growth drivers remaining intact [27] - The company anticipates low single-digit revenue growth for New BD in fiscal 2026, with a positive currency impact expected [23] - Management acknowledged known headwinds in 10% of the portfolio but emphasized strong fundamentals in the remaining 90% [33] Other Important Information - The company is set to close a significant transaction with Waters, receiving a $4 billion cash distribution, with plans to allocate $2 billion for share repurchases and $2 billion for debt paydown [8][24] - The company has reduced its manufacturing network by nearly half, enhancing operational efficiency and cost management [16][56] Q&A Session Summary Question: Guidance for Q2 revenue and EPS - Management indicated that Q2 guidance reflects modest timing benefits and that core growth drivers remain intact, with no ramp expected from Q1 to Q2 [27][28] Question: Structural changes affecting mid-single-digit growth - Management confirmed confidence in the portfolio, noting strong performance in high-growth areas despite known headwinds [33] Question: Impact of Alaris and vaccines in China - Management expects Alaris to step up in 2027, with vaccines anticipated to have a smaller revenue impact moving forward [40][42] Question: M&A opportunities under New BD strategy - The company remains focused on tuck-in M&A that is accretive to revenue and EPS, with a robust pipeline in high-growth sectors [78][80] Question: Pricing environment and potential for price premiums - Management noted a stable pricing environment with slight positive pricing expected outside of China, anticipating improvements as VBP dynamics lessen [91]

Financial Data and Key Metrics Changes - In Q4 2025, NOI increased by 16% sequentially and almost 60% year-over-year, driven by acquisitions and organic growth [12] - Same-property NOI grew by 3.3% for the full year and 1.5% for Q4, despite a 50 basis point headwind from uncollectible revenue [14] - The company is forecasting FFO guidance for 2026 in the range of $1.17 to $1.21 per share, representing a 12% year-over-year growth [15][16] Business Line Data and Key Metrics Changes - The company signed over 400,000 sq ft of new leases and renewals in 2025, with new lease spreads averaging 20% and renewal spreads just under 10% [6] - The lease rate remained unchanged at 96.7%, with occupancy up 20 basis points [13] Market Data and Key Metrics Changes - The total U.S. market for convenience retail assets is 950 million sq ft, significantly larger than the company's current portfolio of almost 5 million sq ft [7] - The company has built a significant network of relationships with sellers and brokers, with 27% of acquisitions being direct and off-market [8] Company Strategy and Development Direction - The company focuses on acquiring top-tier convenience retail assets, emphasizing capital efficiency and a first-mover advantage in the sector [5] - The strategy includes investing in simple, flexible buildings that align with consumer behavior, catering to daily errands rather than destination shopping [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth opportunities in the convenience sector, citing a significant addressable investment market and a strong team to support growth [11] - The company expects to generate double-digit cash flow growth for several years, driven by capital efficiency and reinvestment of retained cash flow [11] Other Important Information - The company ended the year with a leverage ratio of less than 20%, providing substantial liquidity for future acquisitions [19] - The company has a unique capital structure aligned with its business plan, having raised $600 million in debt capital since formation [18] Q&A Session Summary Question: Can you talk about the acquisition pipeline and cap rates? - Management indicated that cap rates have remained just north of 6%, with a wide range depending on various factors [24] - The company has visibility on about half of the $700 million acquisition pipeline for 2026 [25] Question: Can you discuss same-store NOI and leasing spreads? - Management noted that leasing spreads are expected to return to low 20s, and same-property NOI guidance for 2026 is a wide range of 2%-4% [28][30] Question: Are there any operating synergies from having multiple properties in single markets? - Management acknowledged some operational synergies but emphasized that the high recovery rate of the asset class limits their impact on same-store NOI [36] Question: What is the thought process on incremental equity issuance versus building out the debt ladder? - Management highlighted a broad range of options for funding, including equity issuance and private placement, while maintaining a strong liquidity position [52] Question: Are there any planned dispositions for 2026? - Management confirmed that there are no planned dispositions, as the business model focuses on long-term ownership of acquired assets [63][65]

The Hain Celestial Group (NasdaqGS:HAIN) Q2 2026 Earnings call February 09, 2026 08:00 AM ET Company ParticipantsAlexis Tessier - Head of Investor RelationsAlison Lewis - President and CEOAnthony Vendetti - Executive Managing Director of ResearchKaumil Gajrawala - Managing DirectorLee Boyce - CFOConference Call ParticipantsAndrew Lazar - Managing Director and Senior Equity Research AnalystJim Salera - Equity Research AnalystJohn Baumgartner - Managing Director and Senior Equity Research AnalystJon Andersen ...

Aeries Technology (NasdaqCM:AERT) Q3 2026 Earnings call February 09, 2026 08:00 AM ET Company ParticipantsAjay Khare - CEODaniel Webb - CFOOperatorToday, and welcome to Aeries Technology third quarter and fiscal year 2026 earnings call. Joining us today on the call are Aeries Chief Executive Officer Ajay Khare and Chief Financial Officer Daniel Webb. The call will review the results for the quarter ended December 31st, 2025, and outline strategic priorities that are shaping the next stage of our growth. Bef ...

Edgewell Personal Care Company (NYSE:EPC) Q1 2026 Earnings call February 09, 2026 08:00 AM ET Company ParticipantsChris Gough - VP of Investor RelationsFran Weissman - CFOOlivia Tong - Managing DirectorRod Little - President and CEOConference Call ParticipantsChris Carey - Equity Analyst and Head of Consumer Staples ResearchNik Modi - Consumer Staples Equity Research AnalystPeter Grom - Equity Research AnalystSusan Anderson - Managing Director and Senior AnalystOperatorPlease note, this event is being recor ...